Sep. 4 at 10:14 AM
WATCHLIST SEP 04 2025
$IDYA Ideaya Biosciences Enrolls First Patient In Phase 1/2 Trial Of IDE397, A Potential First-In-Class MAT2A Inhibitor, And Trodelvy In MTAP-Deletion Non-Small Cell Lung Cancer
$DOW Dow Launches DOWSIL™ EG-4175 Silicone Gel to Enable Higher Voltage Power Electronics in Electric Vehicles and Renewable Energy Technologies
$SNY Sanofi's Amlitelimab Reinforces Potential As First And Only Atopic Dermatitis Treatment With Possible Dosing Only Four Times Per Year
$EWTX Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
$PRM Perimeter Solutions and USDA Enter Historic Five-Year Agreement, Strengthening Wildfire Response and Expanding Value-Added Services